Goat Anti-Human IgG H&L (HRP) preadsorbed (ab7153)
Key features and details
- Goat Anti-Human IgG H&L (HRP) preadsorbed
- Conjugation: HRP
- Host species: Goat
- Isotype: IgG
- Suitable for: Dot blot, ELISA, IHC-P, WB
製品の概要
-
製品名
Goat Anti-Human IgG H&L (HRP) preadsorbed
IgG 二次抗体 製品一覧 -
由来種
Goat -
ターゲット生物種
Human -
特異性
No reaction was observed against Bovine, Chicken, Goat, Guinea Pig, Hamster, Horse, Mouse, Rabbit, Rat and Sheep Serum Proteins.
-
アプリケーション
適用あり: Dot blot, ELISA, IHC-P, WBmore details -
吸着処理血清
Chicken, Cow, Goat, Guinea pig, Hamster, Horse, Mouse, Rabbit, Rat, Sheep more details -
免疫原
Full length native human IgG (purified).
-
標識
HRP
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C. -
バッファー
pH: 6.50
Preservative: 0.01% Gentamicin sulphate
Constituents: 0.42% Tripotassium orthophosphate, 0.87% Sodium chloride, 1% BSA -
Concentration information loading...
-
精製度
Affinity purified -
特記事項(精製)
HRP Conjugated Secondary Antibody was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. -
特記事項(標識)
Horseradish Peroxidase (HRP) -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab7153の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Dot blot |
Use at an assay dependent concentration.
|
|
ELISA |
1/200000.
|
|
IHC-P |
1/500 - 1/2500.
|
|
WB |
1/1000 - 1/5000.
|
特記事項 |
---|
Dot blot
Use at an assay dependent concentration. |
ELISA
1/200000. |
IHC-P
1/500 - 1/2500. |
WB
1/1000 - 1/5000. |
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
Datasheet download
参考文献 (5)
ab7153 は 5 報の論文で使用されています。
- Han H et al. miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/ß-catenin signaling. Cancer Cell Int 22:42 (2022). PubMed: 35090460
- Weidenbacher PA et al. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Nat Chem Biol 18:1270-1276 (2022). PubMed: 36076082
- Bell BN et al. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library. Protein Sci 30:716-727 (2021). PubMed: 33586288
- Uppu DSSM et al. Temporal release of a three-component protein subunit vaccine from polymer multilayers. J Control Release 317:130-141 (2020). PubMed: 31756392
- Henson D et al. Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events-Brief Report. Arterioscler Thromb Vasc Biol 39:1884-1892 (2019). PubMed: 31315438